Agios Pharmaceuticals has priced an underwritten public offering of 1,986,455 shares of common stock at a price to the public of $110.75 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $220 million.
All of the shares in the offering are to be sold by Agios.
Agios has also granted the underwriters a 30-day option to purchase up to an additional 297,968 shares of common stock on the same terms and conditions.
Closing of the offering is expected to occur on or about December 16, 2014, subject to customary closing conditions.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends